SecBot SecBot
Biotech Drug Report Generated Oct 25, 2026

MAR002

LSTA·LISATA THERAPEUTICS, INC.
NEUTRAL
Drug Impact Rating4/10
Trial phase
Phase 2b
Time to market
Several years away at minimum. Phase 2b data have not yet been reported; even on an accelerated timeline, Phase 3 trials and FDA review would take multiple additional years post-readout. The company is also in corporate restructuring mode post-reverse-merger, which may further delay pipeline execution.
Why 4/10
MAR002 is a Phase 2b asset with no hard dated catalyst in the next ~12 months. The next binary for the stock is the November 9, 2026 shareholder vote on the reverse merger's Series C conversion and Nasdaq listing, which is a corporate (not drug-specific) catalyst. MAR002 is one of two pipeline assets (with MAR001) at a company in restructuring mode; neither drug alone drives the company's near-term thesis. Per the rubric, a mid-stage drug without a dated near-term binary on a multi-asset company caps the score at 5, and the ongoing corporate uncertainty and lack of specific readout timeline justifies 4.
Actionable Insight NEUTRAL

MAR002 has no hard dated catalyst in the next 12 months. The stock's primary near-term binary is the November 9, 2026 shareholder vote on the Series C conversion and reverse stock split, essential for the merged entity's Nasdaq listing. Monitor that vote for trading around the LSTA ticker; the drug-specific readout for MAR002 is likely 12+ months out and should not be the basis for a near-term position.

Price Chart

Loading chart...

Executive Summary

MAR002 is an investigational Phase 2b therapy for acromegaly acquired by Lisata Therapeutics (Nasdaq: LSTA) through its September 2026 reverse merger with Marea Therapeutics, a deal that left legacy Lisata stockholders with only ~2.39% of the combined entity. MAR002 is one of two key pipeline assets (alongside MAR001 for severe hypertriglyceridemia) in Marea's cardioendocrine portfolio. The drug's specific mechanism has not been disclosed, and no Phase 2b data readout date has been set. The near-term stock catalyst is corporate, not drug-specific: the November 9, 2026 shareholder vote needed to complete the merger integration and secure Nasdaq listing. For a NON-MEDICAL investor, MAR002 itself offers no near-term binary catalyst, making it a "watch and wait" pipeline story buried within a complex corporate restructuring.

How It Works

An investigational therapy for acromegaly, a hormonal disorder caused by excess growth hormone (GH) production, typically from a benign pituitary tumor. Acromegaly causes abnormal bone growth, organ enlargement, and metabolic complications. The specific mechanism of MAR002 has not been publicly disclosed, but it targets the growth hormone/IGF-1 axis, likely as a somatostatin analog, growth hormone receptor antagonist, or other endocrine-modulating agent.

Trial Status

MAR002 was in development at Marea Therapeutics prior to Lisata's reverse-merger acquisition closing September 17, 2026. Post-merger SEC filings reference "upcoming Phase 2b data readouts" for MAR002 as a primary value driver, indicating the drug is in Phase 2b testing for acromegaly. No specific clinical trial NCT numbers were found in SecBot's database for MAR002, suggesting it may not yet be registered on ClinicalTrials.gov under this code or may have been conducted under a different identifier. The combined company is currently focused on completing the merger integration, including a November 9, 2026 shareholder vote on Series C conversion and a reverse stock split to meet Nasdaq's $4.00 minimum bid price requirement.

The Two-Sided Case

▲ Bull Case4
Marea's reverse merger brought a ~$225 million PIPE, giving the combined entity a strong balance sheet to fund MAR002's Phase 2b development without near-term dilution risk.
Acromegaly is a well-understood orphan indication with established regulatory pathways and multiple approved comparators, reducing development risk vs. novel targets.
The oral acromegaly market is being validated by PALSONIFY (paltusotine), which Vertex is acquiring Crinetics for ~$10 billion, confirming significant commercial interest in the space.
Veteran biopharma board members (Jeffrey Farrow) with acquisition-exit track records suggest the combined entity may be positioned for a future sale event.
▼ Bear Case5
Legacy Lisata shareholders retain only ~2.39% of the combined entity; the stock's correlation to MAR002's success is extremely diluted for pre-merger holders.
The company faces an existential Nasdaq listing risk, stock trades around $1.00 vs. the $4.00 minimum bid requirement, requiring a reverse split and shareholder approval.
HC Wainwright downgraded LSTA to Neutral from Buy in May 2026, reflecting significant uncertainty around the company's strategic direction.
FINRA short volume ratio was elevated at ~44.8% as of mid-October 2026, indicating notable bearish positioning, and institutional holders like Citadel trimmed positions in Q2 2026.
MAR002 faces intense competition from PALSONIFY (approved oral therapy), established injectable somatostatin analogs (octreotide, lanreotide), and pegvisomant.

Upcoming Catalysts

  • Phase 2b data readout for MAR002 (timing not yet specified, referenced as 'upcoming' in October 2026 SEC filings)
  • November 9, 2026 special shareholder meeting to vote on Series C Preferred Stock conversion and reverse stock split, critical for Nasdaq listing and the merged entity's continued operation

Source Filing

The SecBot filing or press-release report that triggered this drug report:

LISATA THERAPEUTICS, INC. DEF 14A LSTA ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov